Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Phase 2

Terminated

Interventions: Drug: Fostamatinib
Drug: Adalimumab
Drug: Placebo of Adalimumab
Drug: Placebo of Fostamatinib

Brief Summary: This is a sub-study of the OSKIRA-4 study, (D4300C0004, NCT01264770) to explore alternative and more sensitive modalities for measuring the beneficial effects of syk inhibition with fostamatinib in patients with active RA. This MRI sub-study was reported later than the main study due to recruitment delays at specialist imaging sites and so is registered and presented entirely separately to the main study results.

This study will investigate the impact of treatment on joint activity and damage by assessing synovitis, osteitis, bone erosions and joint space narrowing.

Detailed Description: Sub-study to OSKIRA-4: A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Placebo or Adalimumab Monotherapy in Patients with Active Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study Date: 21 March 2011 Version: 1 Primary objective: Assess the efficacy of fostamatinib in reducing joint synovial disease activity as measured by: - Change from baseline to Week 6 (versus placebo) in OMERACT RAMRIS synovitis score.

Recruitment & Eligibility

Inclusion Criteria

Male or female aged 18 and over
Active rheumatoid arthritis (RA) diagnosed after the age of 16
Diagnosis within 5 years prior to study visit 1 and inadequate response to treatment with a maximum 2 Disease-Modifying anti-rheumatic drug (DMARD) therapies, or
diagnosis within 5 years prior to study visit 1 and intolerance to DMARD therapy, or
diagnosis within 2 years prior to study visit 1 and no previous use of DMARDs
4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count)
Either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or
C-Reactive Protein (CRP) blood result of 10mg/L or more
At least 2 of the following:
- documented history or current presence of positive rheumatoid factor (blood test),
- radiographic erosion within 12 months prior to study enrolment,
- presence of serum anti-cyclic citrullinated peptide antibodies (blood test)
- Presence of at least one swollen hand or wrist joint.
- Presence of synovitis on baseline MRI scan, defined as at least 1 joint with RAMRIS synovitis score of +1 or greater.

Exclusion Criteria

Females who are pregnant or breast feeding
Poorly controlled hypertension
Liver disease or significant liver function test abnormalities
Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders
Recent or significant cardiovascular disease
Significant active or recent infection including tuberculosis
Previously received treatment with a TNF alpha antagonist (including etanercept, certolizumab, adalimumab, infliximab, golimumab) or anakinra or previous treatment with other biological agent including rituximab, abatacept and tocilizumab
Use of any DMARDs within 6 weeks before first study visit
Severe renal impairment
Neutropenia
Unable to undergo an MRI examination (e.g. presence of a pacemaker, defibrillator, or other implanted metallic device such as anterior interbody cages, aneurysm clip or pedicle screws)
Known allergy to Gadolinium-based contrast agent,
Tattoos [in area of examination if contains metallic pigment]
Likely to require sedation for the procedure
eGFR less than 55 mL/min

Arm && Interventions

Group	Intervention	Description
Dosing Group A	Placebo of Adalimumab	Oral treatment and subcutaneous injection.
Dosing Group D	Placebo of Fostamatinib	Oral treatment and subcutaneous injection.
Dosing Group E	Fostamatinib	Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
Dosing Group E	Placebo of Adalimumab	Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
Dosing Group E	Placebo of Fostamatinib	Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
Dosing Group A	Fostamatinib	Oral treatment and subcutaneous injection.
Dosing Group D	Adalimumab	Oral treatment and subcutaneous injection.

Primary Outcome Measures

Name	Time	Method
OMERACT RAMRIS Synovitis Score - Comparison of Change From Baseline Between Fostamatinib and Placebo or Adalimumab (Van Elteren)	Baseline, 6 and 24 weeks	OMERACT RAMRIS synovitis score was based on 8 joints, scored from MRI images, and ranged from 0 to 24 with a smaller value indicating a better clinical condition. Median changes from baseline are shown at each visit (defined as post-baseline minus baseline) with negative values indicative of a better clinical condition. BID = twice daily, CI = confidence interval, DMARD = disease-modifying anti-rheumatic drug, IR = inadequate response, MRI = magnetic resonance imaging, OMERACT = Outcome Measures in Rheumatoid Arthritis Clinical Trials, PO = orally, RAMRIS = Rheumatoid Arthritis Magnetic Resonance Image Scoring system, SC = subcutaneous.

Secondary Outcome Measures